BioSpace News Archive

Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSX-V: MDP, OTCQB: PDDPF) today provided an update on its business in light of the recent transformative acquisition of the commercial hematology asset, IXINITY ® , the resulting re-organization and alignment of Medexus’ U.S.-based business and the Company’s ongoing response to the COVID-19 pandemic. With the Company’s acquisition of Aptevo BioTherapeutics LLC (the “

X-ray results and pain and function responses highlight the potential of lorecivivint as a first-in-class drug for the treatment of knee osteoarthritis

Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® has added leading network marketer Daniele Paiola Bellucci to

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it will participate in the Bernstein 36th Annual Strategic Decisions Conference, held virtually, on Friday, May 29, 2020. Geoff Martha, chief executive officer of Medtronic, will make a presentation and will answer questions about the company beginning at 9:00 a.m. EDT (8:00 a.m. CDT). A live webcast of the presentation will be available on May 29, 2020, by cl

Ten new Ohio schools received STEM/STEAM School Designation. The Ohio STEM Committee approved applications for schools that implement best practices in STEM and STEAM education.

The Boettcher Foundation has selected eight researchers to receive funding through the Boettcher Foundation’s Webb-Waring Biomedical Research Awards Program. The recipients, known as Boettcher Investigators, represent five of Colorado’s top research institutions: Colorado College, Colorado State University, National Jewish Health, University of Colorado Ansch

Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the 17th Annual Craig Hallum Institutional Investor Conference taking place on Wednesday, May 27, 2020. Misonix President and Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Misonix

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company that applies its Nucleosomics TM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today the closing of its previously announced underw

INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, announced today that it will effect a 1-for-20 reverse stock split, previously approved by the Company’s Boa

U.S. FDA Approves Takeda’s ALUNBRIG ® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer − Long-Term Results from the Phase 3 ALTA 1L Trial Established ALUNBRIG as a Superior First-Line Treatment Compared to Crizotinib for People with ALK+ Metastatic NSCLC, Including those with Brain Metastases CAMBRIDGE, Mass. & OSAKA, Japan--( BUSINESS WIRE )-- Takeda Pharmaceutical Company Limited (